论文部分内容阅读
冠状动脉介入治疗是目前冠状动脉性心脏病治疗的重要方法,主要包括经皮腔内血管成形术和支架植入术,但术后再狭窄成为另一个难以解决的问题。研究发现,新生内膜过度增长是支架植入术后再狭窄的主要原因,主要与血管平滑肌细胞的过度增殖与迁移以及分泌大量的细胞外基质有关,而且,血管紧张素Ⅱ能促进再狭窄的发展。目前的一些研究显示血管紧张素Ⅱ受体拮抗剂缬沙坦可能降低支架术后的再狭窄率。现对缬沙坦预防冠状动脉支架术后再狭窄的最新进展作一综述。
Coronary artery intervention is an important method for the treatment of coronary heart disease. Percutaneous transluminal angioplasty and stent implantation are the main methods. However, restenosis after surgery is another difficult problem to be solved. The study found that overgrowth of neointimal hyperplasia is the main reason of restenosis after stent implantation, which is mainly related to excessive proliferation and migration of vascular smooth muscle cells and secretion of large amounts of extracellular matrix. Moreover, angiotensin II can promote restenosis development of. Some current studies have shown that the angiotensin Ⅱ receptor antagonist valsartan may reduce the rate of restenosis after stenting. The recent progress of valsartan in prevention of restenosis after coronary stenting is reviewed.